Search 

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.

• To industrialize pluripotent stem cells;
• To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
• To develop major partnerships, particularly in the field of regenerative medicine;
• To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.

Clever Collaboration Group delivers collaboration services allowing organisations to develop and manage collaborate activities and processes with patients, doctors, relatives, any other stakeholder. Example processes our solutions are used in are "Abused Child", "Cold Case (London Police)", "Risk Assessments", North East Essex - Clinical Commissioning Group video in English (http://ccgsweden.com/referenser/vardgivare/north-east-essex.html) .

You can run sessions allowing participants to be anonymous, identified on team level, or with full name. Sessions can be samtime or anytime from anyplace. Police forces typically likes our stand-alone services allowing them to collaborate anywhere without dependancy to internet.

For more information, see www.CCGEurope.com or give us a call at +46 31 - 788 58 50

Best regards

Pierre Wettergren, CEO

ClinTrials Skåne is a public limited company dedicated to helping the life science industry developing their products in close cooperation with universities and the public health care sector in the county of Skåne. We have long experience in working with clinical trials and product development in hospitals in Skåne. Our offices are located in Skåne university hospital and in Medicon Village in Lund, with direct access to both the life science industry and the public healthcare system.

• Dan Peters has >20 years of experience in pharmaceutical discovery and
  development as a key scientific and management leader at NeuroSearch A/S
• PET is a nuclear medicine technique for non-invasive, real-time 3D-imaging
  of physiological processes in the brain and other organs
• Development of best-in-class nicotinic alpha-7 PET ligands (11C-NS14492 and 18F-NS10743)
• 11C-NS14492 and 18F-NS10743 have potential for guiding diagnosis and treatment of Alzheimer’s Disease (Psychopharmacology (2006), 188(4), 509-520)
• High quality NET-PET ligands (11C-NS8880 and 18F-NS12137)
• SERT–PET ligands (11C-NS6417, 11C-NS9531 and 11C-NS9762)
• Broad IP portfolio within several classes with major focus on the EU and US-market
• DanPET owns IP-rights for the ligands mentioned above

Organ and cell transplantations are currently the standard therapy for end-stage organ failure. However, allograft rejections, monitoring of optimal immunosuppression, and shortage of donor organs, are major problems encountered in the field.

The Sahlgrenska Transplantation Unit which is the largest organ transplant clinic in Sweden, has in 2008 made strategic recruitments of a multi-disciplinary team of highly qualified and experienced transplant surgeons and research scientists who, in close collaboration with the clinical transplantation programs, have established the Laboratory for Transplantation and Regenerative Medicine at the Sahlgrenska Academy.

The various projects we present concern:

1) Prevention of allograft rejection by improved donor-recipient selection.
2) Solve organ shortage using two new strategies - namely to avoid allograft rejection by the creation of non-immunogenic scaffolds both for allo- and xenograft rejection and the generation of endothelial and hepatic progenitor cells for transplantation.

We have introduced new specific methods to characterize and assess the importance of alloantibodies, both HLA and non-HLA-specific, as a risk factor for graft rejections. Our efforts aiming at understanding the molecular basis of xenograft rejection will continue, but will focus on delineating the immunogenicity of vascular scaffolds (vessels and heart valves) derived from pig. Such scaffolds may constitute an on-demand source of templates for tissue-engineered vascular grafts.
We have succeeded in isolating human endothelial and liver progenitor cells that not only self-proliferate ex vivo, but also functionally repopulate the damaged organs/tissues of mice with acutely injured organs.
Recently, we have been pioneering in the field of tissue-engineering, creating biocompatible blood vessels for clinical use. Experimental injury models will be used to study mechanisms of human progenitor cell migration, integration and engraftment in the injured tissues. Deciphering mechanisms of stem cell migration and engraftment will provide clinically relevant information that will make tissue repopulation with stem cells more feasible clinically. Tissue-engineered biocompatible tissues or organs using recipient’s autologous stem cells will be a major breakthrough in regenerative medicine and may help solve the organ shortage.

GU Holding is a company owned by the Swedish government. Its mission is to provide funds and business competence for new companies to ensure growth of value and development of companies based on top-notch academic competence and research within University of Gothenburg.

The business concept consists of supplying project and start-up capital together with business competency to add value to and efficiently develop new businesses based on academic leading edge competency and research results. The aim is to create successful growth companies. All projects must be commercially viable, and business ideas and inventions must meet high standards.

GU Holding's mission is to contribute to the development of University of Gothenburg, its staff as well as the whole of the Västra Götaland region. There is close cooperation between the university, including all pursued disciplines, and its various bodies dealing with commercialisation, such as GU Research and Innovation Services.

GU Holding works together with Research and innovationservice at University of Gothenburg. Further, GU Holding has close contact with other innovation actors, such as The Innovation Bridge, Sahlgrenska Science Park, Vinnova, Innovationskontor Väst, Västra Götaland Region and Tillväxtverket as well as business entrepreneurs, private actors within trade and industry or on the capital market, for instance highly esteemed venture capitalists.

The portfolio of GU Holding consists of 33 newly build companies and 14 business projects in many different areas.

GU Holding has invested in pain relief, speaking computers, customized back-in counters, security, oyster farming, a cure for kidney cancer and fish feed ingredient to name a few.

iliod is a pharmaceutical development company aiming at developing a novel infective agent until phase II clinical trials. iliod is founded on the core assets of three patent applications, know-how and experience of the active protein, a network both within academia and industry and a dedicated team with a drive to make a difference for the future of healthcare.

Imaging Resource AB provides advanced microanalysis services of everything from pharmaceutical substances, packaging material, nanostructured surfaces to process equipment and mechanical components.
Scanning Electron Microscopy, as well as other specialized microscopy techniques, is used to increase the knowledge about the properties of your material. We handle projects in many industrial and R&D areas: Life Science, engineering, packaging, material science and product development.

We also create striking scientific illustrations based on Scanning Electron Micrographs. The outcome of your investment in an microscopy analysis can be doubled by refining the result to become fascinating images that can be used in the whole chain from development to marketing.

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be mass-produced.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.